In this study we postulated that quantifying the IL-17 and IL-23 serum levels in patients with IBD could differentiate subgroups of patients with severe and non-severe disease, hence providing a useful clinical tool for patients’ stratification. Here, IL17A is linked to inflammatory bowel disease.